Antibodies that specifically bind human glycoprotein lysosomal membrane 1 (LAMP1) proteins and Masas fascicularis proteins and immunoconjugates that contain these antibodies conjugated to or associated with a growth inhibitory agent are provided. Also provided are pharmaceutical compositions that contain antibodies or immunoconjugates of the invention, and the use of antibodies or immunoconjugates for treating a malignant tumor, as well as antibodies to LAMP1, isolated nucleic acids, vectors and host cells containing the sequence that encodes these antibodies, and using the indicated antibodies as a diagnostic tool. In addition, the application provides for the detection of amplification or the acquisition of the LAMP1 gene in malignant tumor cells, leading to the determination if patients with a malignant tumor are likely to respond to therapy against LAMP1. Consequently, a method has been proposed for selecting an in vitro patient with a malignant tumor, which includes determining, in a biological sample of a patient with a malignant tumor, which contains cells of a malignant tumor, if said patient has an increase in the number of copies of the LAMP1 gene； and patient selection based on the presence of an increase in the number of copies of the LAMP1 gene. In addition, an anti-LAMP1 therapeutic agent is provided for use in the treatment of a malignant tumor in a patient having an increase in the number of copies of the LAMP1 gene in the cells of the malignant tumor.Предоставлены антитела, которые специфически связывают белки гликопротеина лизосомальной мембраны 1 (LAMP1) человека и Масаса fascicularis и иммуноконъюгаты, которые содержат указанные антитела, конъюгированные или связанные с ингибирующим рост средством. Также предоставлены фармацевтические композиции, которые содержат антитела или иммуноконъюгаты по изобретению, и использование антител или иммуноконъюгатов для лечения злокачественной опухоли, а также антитела к LAMP1, выделенные нуклеиновые кислоты, в
